Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12860181 | 0.72 | HTR2A (0.37) | HTR2AHTR2CPARP1KCNH2SLC6A2 | |
| SCHEMBL12860220 | 0.72 | HTR2A (0.37) | HTR2AHTR2CPARP1KCNH2SLC6A2 | |
| SCHEMBL1151085 | 0.72 | HTR2A (0.37) | HTR2AHTR2CPARP1KCNH2SLC6A2 | |
| SCHEMBL4895023 | 0.71 | MTNR1A (0.44) | HTR2AHTR2CPARP1KCNH2KDM4C | |
| SCHEMBL8747325 | 0.66 | PARP1 (0.44) | HTR2AHTR2CPARP1KCNH2SLC6A2 | |
| SCHEMBL3127041 | 0.64 | HTR2A (0.50) | HTR2AHTR2CPARP1KCNH2SLC6A2 | |
| SCHEMBL1150943 | 0.64 | MAOA (0.31) | — | |
| SCHEMBL1150915 | 0.64 | PARP1 (0.51) | HTR2AHTR2CPARP1KCNH2SLC6A2 | |
| SCHEMBL3287609 | 0.64 | PARP1 (0.47) | HTR2AHTR2CPARP1KCNH2SLC6A2 | |
| SCHEMBL1150770 | 0.64 | PARP1 (0.51) | HTR2AHTR2CPARP1KCNH2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | PDE3A, PDE2A, PDE3B | HTR2A 369/4885HTR2C 582/4885PARP1 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.